Alzamend Neuro 10-Q: $7.6M Cash, Going Concern Warning, Material Weakness Persists
ALZN has more than doubled off its 52-week low of $0.84 on light trading volume (0.1× avg).
Summary
Alzamend Neuro's quarterly report shows $7.6M in cash after the Series D financing, but management reiterates going concern doubt and the material weakness in internal controls remains unremediated.
Key Events · Earnings and Guidance · ALZN
-
Cash Position Jumps to $7.6M
Cash increased from $710,689 at April 30, 2026 to $7,591,444 at July 31, 2026, driven by $7.35M net proceeds from Series D Preferred Stock and $669,272 from ATM sales.
-
Going Concern Warning Reiterated
Management states current cash is insufficient to fund planned operations through one year after the financial statement issuance date, creating substantial doubt about the company's ability to continue as a going concern.
-
Material Weakness Unremediated
The material weakness in internal controls over financial reporting, previously disclosed in the FY2026 10-K, remains unremediated as of July 31, 2026 due to insufficient accounting department resources.
-
Series D Conversion Terms Disclosed
Series D Preferred Stock converts at the greater of $0.2668 Floor Price or 80% of the lowest closing bid price over 5 trading days, capped at $2.00 Maximum Price — creating significant potential dilution if converted at the floor.
Analysis · ALZN · Life Sciences
Alzamend Neuro's Q1 FY2027 10-Q shows cash jumped to $7.6M from $710K at fiscal year-end, funded by the $7.35M Series D Preferred Stock sale to Ault Lending and $669K from ATM sales. Despite the capital infusion, management reiterates substantial doubt about the company's ability to continue as a going concern, stating current cash is insufficient to fund operations through one year from issuance. The material weakness in internal controls disclosed in the prior 10-K remains unremediated. The Series D conversion terms — Floor Price $0.2668, Maximum Price $2.00 — create significant potential dilution for existing shareholders if Ault Lending converts at the floor.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALZN was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $0.84 to $2.68. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.